Oxford Nanopore Tech - Appointment of Chief Business Development Officer

Oxford Nanopore Technologies

Tue 07:00

RNS Number : 5868Z
  
Oxford Nanopore Technologies plc
  
20 October 2026
  
 


20 October 2026
Oxford Nanopore Technologies plc
 
("Oxford Nanopore" or the "Company")
 
Appointment of Chief Business Development Officer
 
 
Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing, today announces the appointment of Sebastian Kronmueller as Chief Business Development Officer (CBDO), effective 4 January 2027. He will be based in the United States.
 
Sebastian will lead Oxford Nanopore's strategy and business development functions, including the development and implementation of key strategic initiatives and partnerships.
 
Sebastian joins from Philips, where he is Head of Strategy and Ventures, responsible for global strategy and key inorganic activities. Previously, he spent more than a decade at Siemens Healthineers in senior strategy, business development and operational leadership roles, most recently leading strategy and transformation for its global Diagnostics business.
 
Sebastian brings extensive experience across diagnostics, genomics and biopharma, including acquisitions, divestments, licensing agreements and strategic partnerships. He holds a Master's in Physics from the University of Munich and a Master's in Biomedical Informatics from Stanford University.
 
Francis Van Parys, Chief Executive Officer of Oxford Nanopore, commented: "Sebastian brings a rare combination of strategic insight and hands-on experience building businesses across diagnostics, genomics and healthcare. As Oxford Nanopore grows, we need to be increasingly deliberate about where we focus, where we partner and where we invest. Sebastian will play an important role in accelerating and executing on those decisions to further unlock our significant long-term growth opportunity."
 
Sebastian Kronmueller added: "Oxford Nanopore has built a differentiated technology platform that creates great value for life sciences research, biopharma and clinical applications. What particularly attracted me is the opportunity to help turn that potential into further commercial growth and focused partnerships. I am delighted to join the team at such an important point in the Company's development."
 
 
-ENDS-
 
For further information, please contact:
 
Oxford Nanopore Technologies plc
Investors:     ir@nanoporetech.com
Media:          media@nanoporetech.com
 
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.  Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAEAEENFSEKFAA